Public Release:  JCI early table of contents for May 1, 2013

Journal of Clinical Investigation

HPV leaves its mark in oropharyngeal squamous cell carcinomas

Oropharyngeal squamous cell carcinoma (OPSCC) is a form of cancer that affects the cells lining the middle part of the throat, including the soft palate, the base of the tongue, the tonsils, and the pharynx. High-risk types of human papilloma virus (HPV) are increasingly detected in patients with OPSCC; however, HPV-positive OPSCC is highly curable and patients with HPV have better survival compared to HPV-negative patients, whose cancers are usually associate with alcohol and tobacco use. To understand the molecular mechanisms underlying these differences, Jochen Hess and colleagues at University Hospital Heidelberg in Heidelberg, Germany monitored changes in DNA modifications in HPV-positive and HPV-negative OPSCCs. In this issue of the Journal of Clinical Investigation, they identified a specific pattern of DNA modifications that is dependent on the presence of HPV. This DNA modification pattern was significantly correlated with improved survival in three separate groups of OPSCC patients. This study identifies a specific cellular alteration that can predict clinical outcomes for patients with OPSCC.

TITLE:
HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas

AUTHOR CONTACT:
Jochen Hess
University Hospital Heidelberg, Heidelberg, DEU
Phone: +49 (0)6221 56 39505; E-mail: jochen.hess@med.uni-heidelberg.de

View this article at: http://www.jci.org/articles/view/67010?key=e49a18f8713a54db36d3


Searching for therapeutic synergy in primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies. In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat multiple myeloma and cutaneous T cell lymphoma, respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors. These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.

TITLE:
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma

AUTHOR CONTACT:
Juan Carlos Ramos
Leonard M. Miller School of Medicine, University of Miami, Miamia, FL, USA
Phone: 305-243-6611; Fax: 305-243-5239; E-mail: jramos2@med.miami.edu

View this article at: http://www.jci.org/articles/view/64503?key=911b173313cf3a75e17c


ALSO IN THIS ISSUE

TITLE:
Plasmacytoid dendritic cells promote rotavirus-induced human and murine B-cell responses

AUTHOR CONTACT:
Harry B Greenberg
Stanford University School of Medicine, Stanford, CA, USA
Phone: 650 725 9722; E-mail: harry.greenberg@stanford.edu

View this article at: http://www.jci.org/articles/view/60945?key=92da3ab7cb1e7d28deb4

TITLE:
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

AUTHOR CONTACT:
Pilar Sánchez-Gómez
Instituto de Salud Carlos III-UFIEC, Majadahonda, UNK, ESP
Phone: 34918223265; Fax: 34918223269; E-mail: psanchezg@isciii.es

View this article at: http://www.jci.org/articles/view/63623?key=a0b7cd2c477b6bade3de

TITLE:
PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice

AUTHOR CONTACT:
Zhiwei Chen
AIDS Institute, Hong Kong, HKG
Phone: 85228199831; Fax: 85228199824; E-mail: zchenai@hku.hk

View this article at: http://www.jci.org/articles/view/64704?key=17828494be1b33866ebd

TITLE:
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

AUTHOR CONTACT:
So Young Kim
Duke University, Durham, NC, USA
Phone: 919-684-7955; E-mail: soyoung.kim@duke.edu

View this article at: http://www.jci.org/articles/view/66343?key=13fcaece6930940c5e5a

TITLE:
Fetal-derived adrenomedullin mediates the innate immune milieu of the placenta

AUTHOR CONTACT:
Kathleen M. Caron
The Univ. of North Carolina-Chapel Hill, Chapel Hill, NC, USA
Phone: (919) 966-5215; Fax: (919) 966-5230; E-mail: kathleen_caron@med.unc.edu

View this article at: http://www.jci.org/articles/view/67039?key=3afdba3bdd597a169a37

TITLE:
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance

AUTHOR CONTACT:
Amer Beg
LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, FL, USA
Phone: 813-745-5714; E-mail: amer.beg@moffitt.org

View this article at: http://www.jci.org/articles/view/67250?key=ec2f042511c98c04245d

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.